Immtech Announces Pafuramidine Program on Clinical Hold

Immtech Pharmaceuticals, Inc. announced that it is working with clinical investigators at the South African site where a safety study is in progress for pafuramidine (DB289), an investigational therapy. In preliminary findings from the study, abnormal laboratory values were found in several volunteers following treatment with pafuramidine. The Company has discussed the preliminary findings with the U.S. Food and Drug Administration (USFDA), and as a precautionary measure the pafuramidine program has been placed on clinical hold.
Yahoo! Finance